1 |
dpavlin |
1.1 |
<p><b>ORGANISATIONAL CHANGES</b></p> |
2 |
|
|
<p>Zagreb, 1st July 1999</p> |
3 |
|
|
<p>In response to changes in the environment, and with the aim of generating long-term |
4 |
|
|
growth, PLIVA has defined a new strategy within the activities of its PLIVA |
5 |
|
|
XXI project. The strategy is based on pharmaceuticals being the core-business, |
6 |
|
|
continuously increasing R&D investments and intensifying the internationalisation |
7 |
|
|
of the company.</p> |
8 |
|
|
<p>Defining the strategy was just part of a comprehensive project of transforming |
9 |
|
|
ideas into business success. That is why we have developed or innovated within |
10 |
|
|
the PLIVA XXI project, a whole range of processes and systems which support |
11 |
|
|
the strategy. A new strategic planning process was created, as well as a new |
12 |
|
|
process of introducing and developing new products, internal communication processes |
13 |
|
|
and the most challenging of all, the Customer Intimacy project. The new organisational |
14 |
|
|
structure that supports the strategy is the largest of all the changes and is |
15 |
|
|
being implemented as of 1st July.</p> |
16 |
|
|
<blockquote> |
17 |
|
|
<p> According to the new organisation, the two basic organisational units within |
18 |
|
|
PLIVA Pharmaceuticals are: Pharmaceutical Operations and Technical Operations. |
19 |
|
|
Pharmaceutical Operations focus on creating a long-term strategy of pharmaceutical |
20 |
|
|
development, as well as carrying out that strategy on target markets. Pharmaceutical |
21 |
|
|
Operations consist of Strategic Marketing, Licensing, Medical Affairs and |
22 |
|
|
Marketing and Sales. The objective of Technical Operations is to support the |
23 |
|
|
realisation of corporate goals by rationally using financial, production and |
24 |
|
|
other logistical resources. In addition to Primary and Secondary Production, |
25 |
|
|
Technical Operations consist of Maintenance, Engineering, Raw Materials Purchasing, |
26 |
|
|
Fixed Assets Purchasing and Logistics.</p> |
27 |
|
|
</blockquote> |
28 |
|
|
<p>As a result of the new organisational structure new jobs and responsibilities |
29 |
|
|
have been defined and new managers appointed.</p> |
30 |
|
|
<p>Mr. <b>Zelimir Vuksic</b>, M.D., will be Director of Pharmaceutical Operations. |
31 |
|
|
Until now he worked in Marketing and Sales, where he was Director, and has been |
32 |
|
|
working in PLIVA since January 1997. His experience in Knoll, where he started |
33 |
|
|
his professional career, provided him with knowledge of the pharmaceutical business, |
34 |
|
|
and as Director of Marketing and Sales he got very well acquainted with PLIVA. |
35 |
|
|
Within PLIVA XXI he was Implementation Director responsible for developing the |
36 |
|
|
Customer Intimacy project.</p> |
37 |
|
|
<p>Mr. <b>Velimir Gojnic</b>, B.S. Mechanical Engineering., has been appointed |
38 |
|
|
Director of Technical Operations. Prior to this, he was Business Manager for |
39 |
|
|
Production & Logistics Coca-Cola Beverages Europe plc. in Vienna. Mr. Gojnic's |
40 |
|
|
experience in implementing standard operating procedures with IT support in |
41 |
|
|
sales, production, purchasing, warehousing and distribution for various operations |
42 |
|
|
in 12 countries will contribute to the integration and efficiency of the processes |
43 |
|
|
in PLIVA's Technical Operations.</p> |
44 |
|
|
<p>The Director of Strategic Marketing is <b>Gerard Cole</b>, M.C.S. Mr. Cole |
45 |
|
|
has 21 years of experience in the pharmaceutical industry during which he held |
46 |
|
|
various positions, from Director of the Abbott Scandinavia Division to Independent |
47 |
|
|
Marketing Consultant for leading multinational pharmaceuticals companies.</p> |
48 |
|
|
<p><b>Michele Spelta</b>, M.D., the new Director of Licensing, comes to PLIVA |
49 |
|
|
from the Italian pharmaceuticals company Zambon where he worked in the same |
50 |
|
|
field (International Licensing/Business Development Manager). Before that, Mr. |
51 |
|
|
Spelta worked in the Swiss company Helsinn.</p> |
52 |
|
|
<p>There are changes in the Marketing team as well. The new Product Manager for |
53 |
|
|
the CEFTA countries is <b>Kenneth Peterson</b>, who held the same position in |
54 |
|
|
Pfizer, and the new Product Manager for the countries of the CIS is <b>Massimo |
55 |
|
|
Verenini</b>. <b>Nikolaus Zimmermann-Meinzingen</b> has been appointed Marketing |
56 |
|
|
and Sales Training Manager. Mr. Zimmermann-Meinzingen previously worked in Bayer's |
57 |
|
|
subsidiary in Austria.</p> |
58 |
|
|
<p>The new Director of PLIVA Krakow is <b>Tomasz Jazwinski</b> who built a successful |
59 |
|
|
career in ABB where he also gained valuable experience in management. He has |
60 |
|
|
held various positions, from Manager of Purchasing in ABB Elwy, to Management |
61 |
|
|
Board member in ABB Zwar in Warsaw. His experience in restructuring processes |
62 |
|
|
will be very useful in his new job.</p> |
63 |
|
|
<p><b>Nenad Stiglic</b> is returning to PLIVA as Director of Animal Health as |
64 |
|
|
of 1st July after having worked in the company Veterinaria, where he was head |
65 |
|
|
of foreign representative offices. His knowledge in the field of animal health |
66 |
|
|
and of the Croatian market will enable this segment of PLIVA's operations to |
67 |
|
|
further develop. <b>Marko Smetisko</b>, M.D., and <b>Boris Teski</b> have decided |
68 |
|
|
to leave PLIVA and continue their professional careers in other companies. We |
69 |
|
|
would like to use this opportunity to thank them for their contributions.</p> |
70 |
|
|
<p>We believe that the newly appointed managers are a valuable addition to an |
71 |
|
|
already successful PLIVA team, which will continue to successfully manage changes |
72 |
|
|
and fulfil the set objectives. </p> |